BioCentury
ARTICLE | Emerging Company Profile

Led by Bluestone, Sonoma launches to turn Tregs against autoimmunity

With $40M series A, Sonoma aims to develop Treg-based cell therapies for autoimmune, neurodegenerative diseases

February 7, 2020 1:53 AM UTC
Updated on Feb 7, 2020 at 2:09 AM UTC

Founded by a team of T cell biology pioneers including the Parker Institute’s Jeffrey Bluestone, Sonoma Biotherapeutics launched Thursday with a $40 million series A round to develop Treg-based cell therapies for autoimmune and neurodegenerative diseases.

Sonoma’s investor syndicate includes Lyell Immunopharma Inc., Arch Venture Partners, Milky Way Ventures and 8VC...